Targeting these myeloid populations for activation through CD40 is an essential and unique step to licensing the tumor immune response during KRAS inhibition, enhances preclinical response to SOS1i+MEKi, and can induce checkpoint blockade–mediated complete response. The gene discussed is KRAS; the disease is neoplasm.